Literature DB >> 2445474

Monoclonal antibody technique for detection of estrogen receptors in human breast cancer: greater sensitivity and more accurate classification of receptor status than the dextran-coated charcoal method.

S M Thorpe1.   

Abstract

Estrogen receptor (ER) concentrations have been determined in 191 freshly prepared cytosols from breast cancer biopsies using both the monoclonal enzyme immunoassay (ER-EIA) and the dextran-coated charcoal (ER-DCC) methods in a single laboratory. The concentrations of the ER detected using the two methods are highly and significantly correlated (linear regression curve: ER-EIA = 15.5 + 0.82 ER-DCC; r = 0.97). Nevertheless, it may be most correct to interpret the data by resolving the correlation into two lines, one describing the fit for cytosols with low and intermediate concentrations (the first 75% of the distribution of ER values for all primary breast cancers; less than 217 fmol ER/mg cytosol protein) and one describing the fit for cytosols with the highest ER concentrations (i.e., greater than or equal to 217 fmol ER/mg cytosol protein). Using a cutoff limit of 10 fmol/mg cytosol protein to distinguish between ER positive and ER negative biopsies, discrepancies in the classification of ER status were found in only 6% (12 of 191) of the cases using the two different methods. In all 12 cases, the ER concentrations as determined by both methods were in the lower range of receptor concentrations (0-53 fmol/mg cytosol protein). Of the 12 discrepancies, 10 biopsies were classified as ER negative using the ER-DCC method but ER positive using the ER-EIA method. Additional available data for these 10 patients indicate that the ER-EIA assay yielded the more biologically "correct" result. All 10 of these biopsies were either progesterone receptor positive or had nuclear ER. By identifying the outliers of the linear regression curves (points exceeding the 80% confidence interval) of the logarithmically transformed ER concentrations, 9 of the 12 biopsies were identified. Thus, it is unlikely that the observed discrepancies are due to random events in most cases here. Since most of the few deviations observed appear to represent true differences in the sensitivities of the two methods, the ER-EIA method appears to be superior to the ER-DCC method in our hands. The concentration of ER in 47 cytosols stored at -70 degrees C for 3-6 yr was analyzed using the ER-EIA method, and results were compared to the concentration of ER found using the ER-DCC method on freshly prepared cytosols when the biopsies had been received at the laboratory. The linear regression curve of the correlation between ER concentrations determined using the two methods did not differ significantly from that found for the 191 freshly prepared cytosols.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2445474

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  12 in total

1.  The overall survival of breast cancer patients without adjuvant therapy.

Authors:  Sakura Onishi; Masataka Sawaki; Junko Ishiguro; Ayumi Kataoka; Madoka Iwase; Kayoko Sugino; Yayoi Adachi; Naomi Gondo; Haruru Kotani; Akiyo Yoshimura; Masaya Hattori; Keitaro Matsuo; Yasushi Yatabe; Hiroji Iwata
Journal:  Surg Today       Date:  2019-02-07       Impact factor: 2.549

2.  Comparison of ligand binding assay and enzyme immunoassay of oestrogen receptor in human breast cancer cytosols. Experience of the E.O.R.T.C. Receptor Group.

Authors:  M A Blankenstein
Journal:  Breast Cancer Res Treat       Date:  1990-12       Impact factor: 4.872

3.  Vimentin is preferentially expressed in human breast carcinomas with low estrogen receptor and high Ki-67 growth fraction.

Authors:  W Domagala; J Lasota; J Bartkowiak; K Weber; M Osborn
Journal:  Am J Pathol       Date:  1990-01       Impact factor: 4.307

4.  Immunohistochemical profile of invasive lobular carcinoma of the breast: predominantly vimentin and p53 protein negative, cathepsin D and oestrogen receptor positive.

Authors:  W Domagala; M Markiewski; R Kubiak; J Bartkowiak; M Osborn
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1993

5.  Comparison of new immunohistochemical assay for oestrogen receptor in paraffin wax embedded breast carcinoma tissue with quantitative enzyme immunoassay.

Authors:  G Saccani Jotti; S R Johnston; J Salter; S Detre; M Dowsett
Journal:  J Clin Pathol       Date:  1994-10       Impact factor: 3.411

6.  Inhibitory effects of tamoxifen and tumor necrosis factor alpha on human glioblastoma cells.

Authors:  K Iwasaki; S A Toms; G H Barnett; M L Estes; M K Gupta; B P Barna
Journal:  Cancer Immunol Immunother       Date:  1995-04       Impact factor: 6.968

7.  Quantitative analysis of mutant p53 protein in breast tumor cytosols and study of its association with other biochemical prognostic indicators in breast cancer.

Authors:  M A Levesque; E P Diamandis; H Yu; D J Sutherland
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

Review 8.  Oestrogen receptor: a stable phenotype in breast cancer.

Authors:  J F Robertson
Journal:  Br J Cancer       Date:  1996-01       Impact factor: 7.640

9.  Measurement of oestrogen receptor mRNA levels in human breast tumours.

Authors:  J A Henry; S Nicholson; J R Farndon; B R Westley; F E May
Journal:  Br J Cancer       Date:  1988-11       Impact factor: 7.640

10.  Detection of P24 protein in human breast cancer: influence of receptor status and oestrogen exposure.

Authors:  L Seymour; W R Bezwoda; K Meyer; C Behr
Journal:  Br J Cancer       Date:  1990-06       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.